GLUE
HEALTHCAREMonte Rosa Therapeutics Inc
$20.39+1.04 (+5.37%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GLUE Today?
No stock-specific AI insight has been generated for GLUE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.51$25.77
$20.39
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-0.46
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding80.0M
GLUE News
20 articles- Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesYahoo Finance·May 7, 2026
- Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 6, 2026
- Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 5, 2026
- Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital RaiseMotley Fool·Apr 21, 2026
- Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid TumorsYahoo Finance·Apr 20, 2026
- Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer StoryYahoo Finance·Mar 21, 2026
- Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of US Federal Reserve MeetingYahoo Finance·Mar 17, 2026
- Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plansMarketbeat·Mar 17, 2026
- Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 17, 2026
- Monte Rosa Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 17, 2026
- Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business UpdatesYahoo Finance·Mar 17, 2026
- Agenus (AGEN) Q4 Earnings and Revenues Surpass EstimatesYahoo Finance·Mar 17, 2026
- Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerYahoo Finance·Mar 16, 2026
- Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Yahoo Finance·Mar 12, 2026
- Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public OfferingYahoo Finance·Mar 8, 2026
- How Monte Rosa’s MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE’s Risk‑Reward ProfileYahoo Finance·Mar 8, 2026
- Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 5, 2026
- Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)Yahoo Finance·Feb 24, 2026
- Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 23, 2026
All 20 articles loaded
Price Data
Open$19.41
Previous Close$19.35
Day High$20.72
Day Low$19.12
52 Week High$25.77
52 Week Low$3.51
52-Week Range
$3.51$25.77
$20.39
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-0.46
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding80.0M
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—